CannTrust Holdings Inc (NYSE:CTST) has earned an average broker rating score of 1.75 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating on the company. CannTrust’s rating score has declined by 16.7% in the last three months as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1-year consensus price target of $11.08 for the company and are forecasting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also given CannTrust an industry rank of 65 out of 256 based on the ratings given to its competitors.
CTST has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of CannTrust from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. Bloom Burton reissued an “accumulate” rating on shares of CannTrust in a research note on Friday, March 29th.
CannTrust stock opened at C$5.70 on Friday. The company has a quick ratio of 5.54, a current ratio of 7.65 and a debt-to-equity ratio of 0.06. The stock has a market cap of $714.12 million, a PE ratio of -51.77 and a beta of 4.07. CannTrust has a 1-year low of C$4.35 and a 1-year high of C$11.97.
CannTrust (NYSE:CTST) last posted its earnings results on Thursday, March 28th. The company reported C($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of C($0.04) by C($0.16). The firm had revenue of C$16.20 million for the quarter, compared to analysts’ expectations of C$20.99 million. CannTrust had a negative return on equity of 7.34% and a negative net margin of 28.09%. The company’s quarterly revenue was up 131.4% compared to the same quarter last year. Sell-side analysts predict that CannTrust will post 0.03 earnings per share for the current year.
CannTrust Company Profile
CannTrust Holdings Inc produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital.
Read More: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.